Silence Therapeutics (SLN) Competitors $12.70 -1.28 (-9.16%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLN vs. SYRE, RCUS, OCUL, NTLA, TVTX, SPRY, SNDX, DAWN, PRAX, and SAVAShould you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Intellia Therapeutics (NTLA), Travere Therapeutics (TVTX), ARS Pharmaceuticals (SPRY), Syndax Pharmaceuticals (SNDX), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Silence Therapeutics vs. Spyre Therapeutics Arcus Biosciences Ocular Therapeutix Intellia Therapeutics Travere Therapeutics ARS Pharmaceuticals Syndax Pharmaceuticals Day One Biopharmaceuticals Praxis Precision Medicines Cassava Sciences Spyre Therapeutics (NASDAQ:SYRE) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk. Is SYRE or SLN more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Silence Therapeutics' return on equity of -65.18% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Silence Therapeutics -342.00%-65.18%-34.73% Which has more risk and volatility, SYRE or SLN? Spyre Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Does the MarketBeat Community prefer SYRE or SLN? Silence Therapeutics received 19 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 79.55% of users gave Silence Therapeutics an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesSilence TherapeuticsOutperform Votes3579.55% Underperform Votes920.45% Which has higher valuation & earnings, SYRE or SLN? Silence Therapeutics has higher revenue and earnings than Spyre Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,687.37-$338.79M-$7.47-3.91Silence Therapeutics$31.55M12.05-$53.82M-$1.57-8.09 Does the media favor SYRE or SLN? In the previous week, Spyre Therapeutics had 13 more articles in the media than Silence Therapeutics. MarketBeat recorded 19 mentions for Spyre Therapeutics and 6 mentions for Silence Therapeutics. Spyre Therapeutics' average media sentiment score of 0.51 beat Silence Therapeutics' score of 0.41 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in SYRE or SLN? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate SYRE or SLN? Spyre Therapeutics presently has a consensus price target of $48.57, suggesting a potential upside of 66.34%. Silence Therapeutics has a consensus price target of $57.20, suggesting a potential upside of 350.39%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySpyre Therapeutics beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLN vs. The Competition Export to ExcelMetricSilence TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$380.09M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-8.094.9166.6713.57Price / Sales12.05376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book17.899.686.475.93Net Income-$53.82M$154.43M$119.73M$225.73M7 Day Performance-27.51%-9.46%-5.13%-1.34%1 Month Performance-31.35%-7.27%-2.71%1.15%1 Year Performance39.56%28.13%31.08%24.02% Silence Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNSilence Therapeutics2.9557 of 5 stars$12.70-9.2%$57.20+350.4%+35.0%$380.09M$31.55M-8.09100Analyst ForecastNews CoverageHigh Trading VolumeSYRESpyre Therapeutics2.4611 of 5 stars$29.20-6.6%$48.57+66.3%N/A$1.50B$890,000.00-3.91100Analyst ForecastAnalyst RevisionNews CoverageRCUSArcus Biosciences2.9087 of 5 stars$15.70-0.4%$34.00+116.6%+11.7%$1.44B$117M-4.98500OCULOcular Therapeutix4.0252 of 5 stars$9.16-7.7%$16.71+82.5%+340.4%$1.43B$58.44M-6.94267Analyst ForecastNews CoverageNTLAIntellia Therapeutics4.5396 of 5 stars$13.97-7.6%$55.36+296.3%-46.3%$1.42B$36.28M-2.57600Gap UpTVTXTravere Therapeutics3.1218 of 5 stars$17.72-4.1%$22.62+27.6%+194.8%$1.38B$145.24M-3.89460Analyst ForecastSPRYARS Pharmaceuticals2.6473 of 5 stars$14.01-0.7%$24.00+71.3%+210.6%$1.36B$30,000.00-27.4790Insider SellingAnalyst RevisionNews CoverageSNDXSyndax Pharmaceuticals3.4729 of 5 stars$15.83-5.7%$36.00+127.4%+6.9%$1.35B$139.71M-4.36110Analyst ForecastNews CoverageHigh Trading VolumeDAWNDay One Biopharmaceuticals1.7972 of 5 stars$13.31-7.1%$35.71+168.3%+13.6%$1.34BN/A-12.9260Insider SellingShort Interest ↑PRAXPraxis Precision Medicines1.796 of 5 stars$71.76-6.7%$146.33+103.9%+398.0%$1.34B$2.45M-6.97110Insider SellingNews CoverageSAVACassava Sciences3.7761 of 5 stars$26.91+2.9%$111.50+314.3%+72.0%$1.29BN/A-19.5030High Trading Volume Related Companies and Tools Related Companies SYRE Alternatives RCUS Alternatives OCUL Alternatives NTLA Alternatives TVTX Alternatives SPRY Alternatives SNDX Alternatives DAWN Alternatives PRAX Alternatives SAVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
